Immunostaining of ascitic fluid has revealed high WFDC2 positivity in ovarian cancer (91%), whereas gastric and colorectal cancers exhibit lower positivity rates (25% and 21%, respectively) (20). This evidence concerns the gene WFDC2 and ovarian cancer.